Diabetes: RAS inhibition: Probably not a one-size-fits-all approach

Drazenka Pongrac Barlovic, Mark E. Cooper

Research output: Contribution to journalShort SurveyResearchpeer-review

1 Citation (Scopus)


Blockade of the reninangiotensin system does not seem to prevent early nephropathy in individuals with type 1 diabetes who are normoalbuminuric and normotensive, but both the angiotensin-converting-enzyme inhibitor enalapril and the angiotensin-receptor blocker losartan seem to retard retinopathy.

Original languageEnglish
Pages (from-to)669-670
Number of pages2
JournalNature Reviews Nephrology
Issue number12
Publication statusPublished - Dec 2009
Externally publishedYes

Cite this